Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

New partners ink China-based deal
May 2013
SHARING OPTIONS:

WALTHAM, Mass.X-BODY Biosciences, a developer of therapeutic antibodies with a focus on integral membrane proteins, has inked an exclusive alliance with Jiangsu Hengrui Medicine Co. Ltd. focused on age-related macular degeneration (AMD). Under the agreement, Hengrui will develop and commercialize a novel antibody program generated from X-BODY's antibody platform for AMD in greater China, including mainland China, Taiwan, Macao and Hong Kong. Hengrui will be responsible for funding and leading all preclinical and clinical development and commercialization in the selected markets. X-BODY will retain all development and commercialization rights outside of greater China. Though specific financial details were not released, the agreement is noted as a "multi-million dollar" deal and will include an upfront payment as well as clinical, regulatory and commercialization milestones and royalties on commercialized product revenue.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.